Funding for this research was provided by:
Australian Respiratory Council
Received: 7 May 2019
Accepted: 31 July 2019
First Online: 10 September 2019
Ethics approval and consent to participate
: This study was approved by the Barwon Health Human Research Ethics Committee (reference: 17/15). This approval has been noted by the Deakin University Human Research Ethics Committee. All participants will provide informed written consent before participating. This trial has been further approved by the Cancer Council Victoria Human Research Ethics Committee to access records associated with QuitCoach.
: Our participant information and consent form addresses publication consent and each participant is explained and signs this document at the first meeting with researchers.
: S Dodd has received grant support from Stanley Medical Research Institute, the NHMRC, Beyond Blue, Australian Rotary Health (ARHRF), the Simons Foundation, the Geelong Medical Research Foundation, the Fondation FondaMental, the Harry Windsor Foundation, Eli Lilly and Company, GlaxoSmithKline, Organon, Mayne Pharma and Servier. He has also received speaker’s fees from Eli Lilly and Company and advisory board fees from Eli Lilly and Company and Novartis as well as conference travel support from Servier. M Berk has received grant support from the National Institutes of Health, the Simons Autism Foundation, the Cancer Council of Victoria, the CRC for Mental Health, the Stanley Medical Research Foundation, MBF, the NHMRC, Beyond Blue, the Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, and Company GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier. He has also been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck & Co, Pfizer, Sanofi, Servier, Solvay and Wyeth, and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen Cilag, Lundbeck and Servier and is a co-inventor on two provisional patents regarding the use of NAC and related compounds for psychiatric indications, assigned to the Mental Health Research Institute. OM Dean is a R.D. Wright NHMRC Biomedical Research Fellow (APP 1145634) and has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC and ASBDD/Servier. She has also received in kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.